AI-based digital pathology with platforms for clinical diagnostics and pharmaceutical research.
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Debt Deciphex secured €15 million in growth debt from Claret Capital Partners to grow in the United States and the United Kingdom. | $17.4M |
| Oct 2023 | Debt Dublin pathology-AI company Deciphex raised 10m EUR in venture debt from Claret Capital Partners to expand its Diagnexia service and grow its team. | $10.8M |
| Jan 2023 | Series B Dublin pathology-AI company Deciphex raised an additional 3.9m EUR in Series B funding led by Seroba Life Sciences, bringing the round to 14.4m EUR. | $4.2M |
| May 2022 | Series B Dublin pathology-AI start-up Deciphex raised an $11.5m Series B led by Act Venture Capital (Charles River, Novartis) to launch Diagnexia in the US. | $11.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.